Weitao Fu

1.4k total citations
43 papers, 1.2k citations indexed

About

Weitao Fu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Weitao Fu has authored 43 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Genetics. Recurrent topics in Weitao Fu's work include Prostate Cancer Treatment and Research (9 papers), Estrogen and related hormone effects (8 papers) and Computational Drug Discovery Methods (7 papers). Weitao Fu is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Estrogen and related hormone effects (8 papers) and Computational Drug Discovery Methods (7 papers). Weitao Fu collaborates with scholars based in China, United States and India. Weitao Fu's co-authors include Guang Liang, Lingfeng Chen, Lulu Zheng, Tingjun Hou, Zhiguo Liu, Yi Wang, Yali Zhang, Zheng Xu, Yuanyuan Qian and Weixin Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Agricultural and Food Chemistry.

In The Last Decade

Weitao Fu

41 papers receiving 1.2k citations

Peers

Countries citing papers authored by Weitao Fu

Since Specialization

Citations

This map shows the geographic impact of Weitao Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weitao Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weitao Fu more than expected).

Fields of papers citing papers by Weitao Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weitao Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weitao Fu. The network helps show where Weitao Fu may publish in the future.

Co-authorship network of co-authors of Weitao Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Weitao Fu. A scholar is included among the top collaborators of Weitao Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weitao Fu. Weitao Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of N-(1,2,4-Thiadiazol-5-yl)benzo[b]oxepine-4-carboxamide Derivatives as Novel Antiresistance Androgen Receptor Antagonists 2025 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Ying Wang, Xinyue Wang, Xin Chai, Huating Wang, Lei Xu, (unknown), Xiaohong Xu, Weitao Fu, Peichen Pan, Tingjun Hou, Rong Sheng, Dan Li	0
2	Discovery of 5-Nitro-N-(3-(trifluoromethyl)phenyl) Pyridin-2-amine as a Novel Pure Androgen Receptor Antagonist against Antiandrogen Resistance 2024 ·Journal of Medicinal Chemistry ·Huating Wang, Xuwen Wang, Haiyang Zhong, (unknown), Weitao Fu, Xin Chai, (unknown), Rong Sheng, (unknown), Xiaohong Xu, Lei Xu, Peichen Pan, Tingjun Hou, Dan Li	1
3	Discovery of Thiadiazoleamide Derivatives as Potent, Selective, and Orally Available Antagonists Disrupting Androgen Receptor Homodimer 2024 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Weitao Fu, (unknown), Xin Chai, (unknown), Xiaohong Xu, Tingjun Hou, Rong Sheng, Dan Li	1
4	Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer 2024 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), Yanzhen Yu, (unknown), (unknown), Weitao Fu, (unknown), Tingjun Hou, Dan Li, Rong Sheng	4
5	Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment 2023 ·European Journal of Medicinal Chemistry ·(unknown), Weitao Fu, Jingjing Shao, (unknown), (unknown), Ying Xu, (unknown), Zenghui Ye, Lulu Zheng, Lei Zheng, Jie Yu, Yawen Zhang, Lina Yin, Linglan Tu, (unknown), Jie Li, Guang Liang, Lingfeng Chen	9
6	Small-Molecule Inhibition of Androgen Receptor Dimerization as a Strategy against Prostate Cancer 2023 ·ACS Central Science ·Weitao Fu, Hao Yang, (unknown), (unknown), Zhou Gong, (unknown), Shuai Yang, (unknown), (unknown), Rong Sheng, Zhiguo Zhang, Xiaojun Yao, Chun Tang, Dan Li, Tingjun Hou	12
7	Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer 2023 ·Journal of Medicinal Chemistry ·(unknown), Yingying Li, (unknown), Yuhan Wang, Jiaqi Cao, Weitao Fu, (unknown), Lei Zheng, Longguang Tang, (unknown), Lulu Zheng, Guang Liang, Lingfeng Chen	24
8	Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers 2021 ·Journal of Medicinal Chemistry ·Weitao Fu, (unknown), (unknown), Qing Tang, (unknown), Zhou Gong, (unknown), Mojie Duan, Xin Chai, Jinping Pang, Chun Tang, Xuwen Wang, Xiaohong Xu, Dan Li, Rong Sheng, Tingjun Hou	15
9	Discovery of Novel GR Ligands toward Druggable GR Antagonist Conformations Identified by MD Simulations and Markov State Model Analysis 2021 ·Advanced Science ·Xueping Hu, Jinping Pang, Jintu Zhang, Chao Shen, Xin Chai, Ercheng Wang, (unknown), Xuwen Wang, Mojie Duan, Weitao Fu, Lei Xu, Yu Kang, Dan Li, Hongguang Xia, Tingjun Hou	35
10	Advances in the computational development of androgen receptor antagonists 2020 ·Drug Discovery Today ·Xueping Hu, Xin Chai, Xuwen Wang, Mojie Duan, Jinping Pang, Weitao Fu, Dan Li, Tingjun Hou	21
11	Design and Synthesis of Novel Nordihydroguaiaretic Acid (NDGA) Analogues as Potential FGFR1 Kinase Inhibitors With Anti-Gastric Activity and Chemosensitizing Effect 2020 ·Frontiers in Pharmacology ·Qian Chen, Min Zhu, Jingwen Xie, Zhaojun Dong, (unknown), Di Yun, Weitao Fu, Ledan Wang, Tao Wei, Zhiguo Liu, Peihong Qiu, Jianzhang Wu, Wulan Li	3
12	Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation 2020 ·European Journal of Medicinal Chemistry ·Qin Tang, Weitao Fu, (unknown), Ercheng Wang, (unknown), Xin Chai, Jinping Pang, Xuwen Wang, Xiaohong Xu, Lei Xu, Dan Li, Rong Sheng, Tingjun Hou	18
13	Discovery of Novel Androgen Receptor Ligands by Structure-Based Virtual Screening and Bioassays 2018 ·Genomics Proteomics & Bioinformatics ·Wenfang Zhou, Mojie Duan, Weitao Fu, Jinping Pang, Qin Tang, Huiyong Sun, Lei Xu, Shan Chang, Dan Li, Tingjun Hou	39
14	Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator 2018 ·Journal of Chemical Information and Modeling ·Na Liu, Wenfang Zhou, Yue Guo, Junmei Wang, Weitao Fu, Huiyong Sun, Dan Li, Mojie Duan, Tingjun Hou	40
15	Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer 2017 ·Journal of Medicinal Chemistry ·Lingfeng Chen, Weitao Fu, Lulu Zheng, Zhiguo Liu, Guang Liang	114
16	Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC 2017 ·European Journal of Medicinal Chemistry ·Lingfeng Chen, Weitao Fu, Feng Chen, Rong Qu, Linjiang Tong, Lulu Zheng, (unknown), (unknown), Jie Hu, Yuepiao Cai, Jianpeng Feng, Hua Xie, Jian Ding, Zhiguo Liu, Guang Liang	19
17	A novel non-ATP competitive FGFR1 inhibitor with therapeutic potential on gastric cancer through inhibition of cell proliferation, survival and migration 2017 ·APOPTOSIS ·Jianzhang Wu, Xiaojing Du, Wulan Li, Yangyang Zhou, (unknown), (unknown), Qiuxiang Chen, Weitao Fu, Di Yun, Qing Xu, Peihong Qiu, Rong Jin, Yuepiao Cai, Guang Liang	10
18	Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators 2016 ·Bioorganic & Medicinal Chemistry ·Lei Wang, Li Li, Weitao Fu, Zhengyu Jiang, Qidong You, Xiaoli Xu	19
19	Development of resveratrol-curcumin hybrids as potential therapeutic agents for inflammatory lung diseases 2016 ·European Journal of Medicinal Chemistry ·(unknown), Tingting Xu, Fengli Xu, Yali Zhang, Zhiguo Liu, Wenbo Chen, Weitao Fu, Yuanrong Dai, Yunjie Zhao, Jianpeng Feng, Guang Liang	26
20	Insights into the binding mode of curcumin to MD-2: studies from molecular docking, molecular dynamics simulations and experimental assessments 2015 ·Molecular BioSystems ·Zhe Wang, Gaozhi Chen, Linfeng Chen, Xing Liu, Weitao Fu, Yali Zhang, Chenglong Li, Guang Liang, Yuepiao Cai	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact